Search

Wal-yan Centre welcomes new PhD scholarship awardee

The Wal-yan Respiratory Research Centre this month welcomed new PhD scholarship awardee Yaqin Alziyadat, whose exciting research work will support the Centre’s vision to ensure all children have healthy lungs for life.

Research to help identify which children will develop asthma and to design more specific asthma treatments supported by Federal Government funding

Research focussed on identifying which children will develop asthma, and developing more specific asthma treatments, has been supported by the National Health and Medical Research Council’s (NHMRC) Ideas Grants announced by the Federal Government on 14 December 2022.

AERIAL allergy and asthma study celebrates recruitment of final baby

The AERIAL study, in partnership with The ORIGINS Project, endeavours to understand if exposures during pregnancy and early life can affect the cells lining the airways in newborns, and whether this is associated with the development of wheeze, allergy and asthma later in childhood.

International trial shows that interferon could help reduce the spread of COVID-19

Results of an innovative clinical trial led by Perth researchers have shown that the drug interferon could help reduce the spread of COVID-19 from a positive person to their household contacts, with the study helping to inform treatment options for a future pandemic.

Keelan has ‘survived and thrived’, thanks to research

Ten-year-old Keelan Mullins is known to his mum Clare Hindle as her ‘miracle baby’. Keelan was born in March 2013 at 26 weeks’ gestation and weighing just 1096 grams.

The Wal-yan Respiratory Research Centre turns three!

As the Wal-yan Respiratory Research Centre turns three, we celebrate our achievements, and say thank you to our amazing community.

Perth campaign aims to raise awareness of dangers of a chronic wet cough in Aboriginal children

An intensive health promotion campaign which aims to raise awareness of the dangers of a chronic wet cough in Aboriginal children launched this month in Perth.

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine(PNEU-PLAN)

Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV.

Feasibility of unsedated lung MRI in young children with cystic fibrosis

Kathryn Ramsey BSc (Hons), PhD Co-Head, Foundations of Lung Disease kathryn.ramsey@thekids.org.au Co-Head, Foundations of Lung Disease Associate

Healthy Environments and Lives (HEAL): Australian research network in human health and environmental change

The HEAL Network aims to strengthen the Australian health system and community resilience to climate change, extreme events, and environmental degradation.